Assessing the barriers to image-guided drug delivery
Imaging has become a cornerstone for medical diagnosis and the guidance of patient management. A new field called image‐guided drug delivery (IGDD) now combines the vast potential of the radiological sciences with the delivery of treatment and promises to fulfill the vision of personalized medicine....
Gespeichert in:
| Veröffentlicht in: | Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology 2014-01, Vol.6 (1), p.1-14 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 14 |
|---|---|
| container_issue | 1 |
| container_start_page | 1 |
| container_title | Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology |
| container_volume | 6 |
| creator | Lanza, Gregory M. Moonen, Chrit Baker Jr, James R. Chang, Esther Cheng, Zheng Grodzinski, Piotr Ferrara, Katherine Hynynen, Kullervo Kelloff, Gary Lee, Yong-Eun Koo Patri, Anil K. Sept, David Schnitzer, Jan E. Wood, Bradford J. Zhang, Miqin Zheng, Gang Farahani, Keyvan |
| description | Imaging has become a cornerstone for medical diagnosis and the guidance of patient management. A new field called image‐guided drug delivery (IGDD) now combines the vast potential of the radiological sciences with the delivery of treatment and promises to fulfill the vision of personalized medicine. Whether imaging is used to deliver focused energy to drug‐laden particles for enhanced, local drug release around tumors, or it is invoked in the context of nanoparticle‐based agents to quantify distinctive biomarkers that could risk stratify patients for improved targeted drug delivery efficiency, the overarching goal of IGDD is to use imaging to maximize effective therapy in diseased tissues and to minimize systemic drug exposure in order to reduce toxicities. Over the last several years, innumerable reports and reviews covering the gamut of IGDD technologies have been published, but inadequate attention has been directed toward identifying and addressing the barriers limiting clinical translation. In this consensus opinion, the opportunities and challenges impacting the clinical realization of IGDD‐based personalized medicine were discussed as a panel and recommendations were proffered to accelerate the field forward. WIREs Nanomed Nanobiotechnol 2014, 6:1–14. doi: 10.1002/wnan.1247
This article is categorized under:
Therapeutic Approaches and Drug Discovery > Emerging Technologies
Diagnostic Tools > In Vivo Nanodiagnostics and Imaging
Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease |
| doi_str_mv | 10.1002/wnan.1247 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1635020507</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3788832731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4877-45b9fb0f263d107048c7df9555cefbe98fe50ff523f4ea5aecbb669802dfd8223</originalsourceid><addsrcrecordid>eNqF0U9P2zAYBnALbaLAduALoEi7sEPa1__jY6k2QOqYtG7iaCXx6xKWJsVuVvrtSdXCAQl2sg-_95H9PoScUhhSADZaN3kzpEzoA3JEDTcpgKAf9ndJqRqQ4xjvAZRQTB6SAROcGy7VERHjGDHGqpknqztMijyECkNMVm1SLfI5pvOucugSF7p54rCu_mHYfCIffV5H_Lw_T8if799-T67S6c_L68l4mpYi0zoVsjC-AM8UdxQ0iKzUzhspZYm-QJN5lOC9ZNwLzGWOZVEoZTJgzruMMX5Czne5y9A-dBhXdlHFEus6b7DtoqWKS2AgQf-fCq2lzIzZpn55Re_bLjT9RywD0Eb0D6TvKapBC54JyXv1dafK0MYY0Ntl6PcWNpaC3XZjt93YbTe9PdsndsUC3Yt8LqMHox1YVzVu3k6ytzfjm31kupuo4gofXyby8NcqzbXs5aWdzaa_Lm7ND8v5E6m1pYI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1707438453</pqid></control><display><type>article</type><title>Assessing the barriers to image-guided drug delivery</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Lanza, Gregory M. ; Moonen, Chrit ; Baker Jr, James R. ; Chang, Esther ; Cheng, Zheng ; Grodzinski, Piotr ; Ferrara, Katherine ; Hynynen, Kullervo ; Kelloff, Gary ; Lee, Yong-Eun Koo ; Patri, Anil K. ; Sept, David ; Schnitzer, Jan E. ; Wood, Bradford J. ; Zhang, Miqin ; Zheng, Gang ; Farahani, Keyvan</creator><creatorcontrib>Lanza, Gregory M. ; Moonen, Chrit ; Baker Jr, James R. ; Chang, Esther ; Cheng, Zheng ; Grodzinski, Piotr ; Ferrara, Katherine ; Hynynen, Kullervo ; Kelloff, Gary ; Lee, Yong-Eun Koo ; Patri, Anil K. ; Sept, David ; Schnitzer, Jan E. ; Wood, Bradford J. ; Zhang, Miqin ; Zheng, Gang ; Farahani, Keyvan</creatorcontrib><description>Imaging has become a cornerstone for medical diagnosis and the guidance of patient management. A new field called image‐guided drug delivery (IGDD) now combines the vast potential of the radiological sciences with the delivery of treatment and promises to fulfill the vision of personalized medicine. Whether imaging is used to deliver focused energy to drug‐laden particles for enhanced, local drug release around tumors, or it is invoked in the context of nanoparticle‐based agents to quantify distinctive biomarkers that could risk stratify patients for improved targeted drug delivery efficiency, the overarching goal of IGDD is to use imaging to maximize effective therapy in diseased tissues and to minimize systemic drug exposure in order to reduce toxicities. Over the last several years, innumerable reports and reviews covering the gamut of IGDD technologies have been published, but inadequate attention has been directed toward identifying and addressing the barriers limiting clinical translation. In this consensus opinion, the opportunities and challenges impacting the clinical realization of IGDD‐based personalized medicine were discussed as a panel and recommendations were proffered to accelerate the field forward. WIREs Nanomed Nanobiotechnol 2014, 6:1–14. doi: 10.1002/wnan.1247
This article is categorized under:
Therapeutic Approaches and Drug Discovery > Emerging Technologies
Diagnostic Tools > In Vivo Nanodiagnostics and Imaging
Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease</description><identifier>ISSN: 1939-5116</identifier><identifier>EISSN: 1939-0041</identifier><identifier>DOI: 10.1002/wnan.1247</identifier><identifier>PMID: 24339356</identifier><language>eng</language><publisher>Hoboken, USA: John Wiley & Sons, Inc</publisher><subject>Animals ; Biomarkers ; Diagnostic software ; Diagnostic systems ; Drug delivery ; Drug Delivery Systems ; Drug discovery ; Humans ; Imaging ; Medical equipment ; Medicine ; Mice ; Molecular Imaging ; Nanomedicine ; Nanoparticles ; Nanotechnology ; Pharmaceutical industry ; Precision Medicine ; Tissues ; Toxicity ; Tumors</subject><ispartof>Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 2014-01, Vol.6 (1), p.1-14</ispartof><rights>2013 Wiley Periodicals, Inc.</rights><rights>Copyright © 2014 Wiley Periodicals, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4877-45b9fb0f263d107048c7df9555cefbe98fe50ff523f4ea5aecbb669802dfd8223</citedby><cites>FETCH-LOGICAL-c4877-45b9fb0f263d107048c7df9555cefbe98fe50ff523f4ea5aecbb669802dfd8223</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fwnan.1247$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fwnan.1247$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24339356$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lanza, Gregory M.</creatorcontrib><creatorcontrib>Moonen, Chrit</creatorcontrib><creatorcontrib>Baker Jr, James R.</creatorcontrib><creatorcontrib>Chang, Esther</creatorcontrib><creatorcontrib>Cheng, Zheng</creatorcontrib><creatorcontrib>Grodzinski, Piotr</creatorcontrib><creatorcontrib>Ferrara, Katherine</creatorcontrib><creatorcontrib>Hynynen, Kullervo</creatorcontrib><creatorcontrib>Kelloff, Gary</creatorcontrib><creatorcontrib>Lee, Yong-Eun Koo</creatorcontrib><creatorcontrib>Patri, Anil K.</creatorcontrib><creatorcontrib>Sept, David</creatorcontrib><creatorcontrib>Schnitzer, Jan E.</creatorcontrib><creatorcontrib>Wood, Bradford J.</creatorcontrib><creatorcontrib>Zhang, Miqin</creatorcontrib><creatorcontrib>Zheng, Gang</creatorcontrib><creatorcontrib>Farahani, Keyvan</creatorcontrib><title>Assessing the barriers to image-guided drug delivery</title><title>Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology</title><addtitle>WIREs Nanomed Nanobiotechnol</addtitle><description>Imaging has become a cornerstone for medical diagnosis and the guidance of patient management. A new field called image‐guided drug delivery (IGDD) now combines the vast potential of the radiological sciences with the delivery of treatment and promises to fulfill the vision of personalized medicine. Whether imaging is used to deliver focused energy to drug‐laden particles for enhanced, local drug release around tumors, or it is invoked in the context of nanoparticle‐based agents to quantify distinctive biomarkers that could risk stratify patients for improved targeted drug delivery efficiency, the overarching goal of IGDD is to use imaging to maximize effective therapy in diseased tissues and to minimize systemic drug exposure in order to reduce toxicities. Over the last several years, innumerable reports and reviews covering the gamut of IGDD technologies have been published, but inadequate attention has been directed toward identifying and addressing the barriers limiting clinical translation. In this consensus opinion, the opportunities and challenges impacting the clinical realization of IGDD‐based personalized medicine were discussed as a panel and recommendations were proffered to accelerate the field forward. WIREs Nanomed Nanobiotechnol 2014, 6:1–14. doi: 10.1002/wnan.1247
This article is categorized under:
Therapeutic Approaches and Drug Discovery > Emerging Technologies
Diagnostic Tools > In Vivo Nanodiagnostics and Imaging
Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease</description><subject>Animals</subject><subject>Biomarkers</subject><subject>Diagnostic software</subject><subject>Diagnostic systems</subject><subject>Drug delivery</subject><subject>Drug Delivery Systems</subject><subject>Drug discovery</subject><subject>Humans</subject><subject>Imaging</subject><subject>Medical equipment</subject><subject>Medicine</subject><subject>Mice</subject><subject>Molecular Imaging</subject><subject>Nanomedicine</subject><subject>Nanoparticles</subject><subject>Nanotechnology</subject><subject>Pharmaceutical industry</subject><subject>Precision Medicine</subject><subject>Tissues</subject><subject>Toxicity</subject><subject>Tumors</subject><issn>1939-5116</issn><issn>1939-0041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0U9P2zAYBnALbaLAduALoEi7sEPa1__jY6k2QOqYtG7iaCXx6xKWJsVuVvrtSdXCAQl2sg-_95H9PoScUhhSADZaN3kzpEzoA3JEDTcpgKAf9ndJqRqQ4xjvAZRQTB6SAROcGy7VERHjGDHGqpknqztMijyECkNMVm1SLfI5pvOucugSF7p54rCu_mHYfCIffV5H_Lw_T8if799-T67S6c_L68l4mpYi0zoVsjC-AM8UdxQ0iKzUzhspZYm-QJN5lOC9ZNwLzGWOZVEoZTJgzruMMX5Czne5y9A-dBhXdlHFEus6b7DtoqWKS2AgQf-fCq2lzIzZpn55Re_bLjT9RywD0Eb0D6TvKapBC54JyXv1dafK0MYY0Ntl6PcWNpaC3XZjt93YbTe9PdsndsUC3Yt8LqMHox1YVzVu3k6ytzfjm31kupuo4gofXyby8NcqzbXs5aWdzaa_Lm7ND8v5E6m1pYI</recordid><startdate>201401</startdate><enddate>201401</enddate><creator>Lanza, Gregory M.</creator><creator>Moonen, Chrit</creator><creator>Baker Jr, James R.</creator><creator>Chang, Esther</creator><creator>Cheng, Zheng</creator><creator>Grodzinski, Piotr</creator><creator>Ferrara, Katherine</creator><creator>Hynynen, Kullervo</creator><creator>Kelloff, Gary</creator><creator>Lee, Yong-Eun Koo</creator><creator>Patri, Anil K.</creator><creator>Sept, David</creator><creator>Schnitzer, Jan E.</creator><creator>Wood, Bradford J.</creator><creator>Zhang, Miqin</creator><creator>Zheng, Gang</creator><creator>Farahani, Keyvan</creator><general>John Wiley & Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7QP</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>201401</creationdate><title>Assessing the barriers to image-guided drug delivery</title><author>Lanza, Gregory M. ; Moonen, Chrit ; Baker Jr, James R. ; Chang, Esther ; Cheng, Zheng ; Grodzinski, Piotr ; Ferrara, Katherine ; Hynynen, Kullervo ; Kelloff, Gary ; Lee, Yong-Eun Koo ; Patri, Anil K. ; Sept, David ; Schnitzer, Jan E. ; Wood, Bradford J. ; Zhang, Miqin ; Zheng, Gang ; Farahani, Keyvan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4877-45b9fb0f263d107048c7df9555cefbe98fe50ff523f4ea5aecbb669802dfd8223</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Biomarkers</topic><topic>Diagnostic software</topic><topic>Diagnostic systems</topic><topic>Drug delivery</topic><topic>Drug Delivery Systems</topic><topic>Drug discovery</topic><topic>Humans</topic><topic>Imaging</topic><topic>Medical equipment</topic><topic>Medicine</topic><topic>Mice</topic><topic>Molecular Imaging</topic><topic>Nanomedicine</topic><topic>Nanoparticles</topic><topic>Nanotechnology</topic><topic>Pharmaceutical industry</topic><topic>Precision Medicine</topic><topic>Tissues</topic><topic>Toxicity</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lanza, Gregory M.</creatorcontrib><creatorcontrib>Moonen, Chrit</creatorcontrib><creatorcontrib>Baker Jr, James R.</creatorcontrib><creatorcontrib>Chang, Esther</creatorcontrib><creatorcontrib>Cheng, Zheng</creatorcontrib><creatorcontrib>Grodzinski, Piotr</creatorcontrib><creatorcontrib>Ferrara, Katherine</creatorcontrib><creatorcontrib>Hynynen, Kullervo</creatorcontrib><creatorcontrib>Kelloff, Gary</creatorcontrib><creatorcontrib>Lee, Yong-Eun Koo</creatorcontrib><creatorcontrib>Patri, Anil K.</creatorcontrib><creatorcontrib>Sept, David</creatorcontrib><creatorcontrib>Schnitzer, Jan E.</creatorcontrib><creatorcontrib>Wood, Bradford J.</creatorcontrib><creatorcontrib>Zhang, Miqin</creatorcontrib><creatorcontrib>Zheng, Gang</creatorcontrib><creatorcontrib>Farahani, Keyvan</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lanza, Gregory M.</au><au>Moonen, Chrit</au><au>Baker Jr, James R.</au><au>Chang, Esther</au><au>Cheng, Zheng</au><au>Grodzinski, Piotr</au><au>Ferrara, Katherine</au><au>Hynynen, Kullervo</au><au>Kelloff, Gary</au><au>Lee, Yong-Eun Koo</au><au>Patri, Anil K.</au><au>Sept, David</au><au>Schnitzer, Jan E.</au><au>Wood, Bradford J.</au><au>Zhang, Miqin</au><au>Zheng, Gang</au><au>Farahani, Keyvan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Assessing the barriers to image-guided drug delivery</atitle><jtitle>Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology</jtitle><addtitle>WIREs Nanomed Nanobiotechnol</addtitle><date>2014-01</date><risdate>2014</risdate><volume>6</volume><issue>1</issue><spage>1</spage><epage>14</epage><pages>1-14</pages><issn>1939-5116</issn><eissn>1939-0041</eissn><abstract>Imaging has become a cornerstone for medical diagnosis and the guidance of patient management. A new field called image‐guided drug delivery (IGDD) now combines the vast potential of the radiological sciences with the delivery of treatment and promises to fulfill the vision of personalized medicine. Whether imaging is used to deliver focused energy to drug‐laden particles for enhanced, local drug release around tumors, or it is invoked in the context of nanoparticle‐based agents to quantify distinctive biomarkers that could risk stratify patients for improved targeted drug delivery efficiency, the overarching goal of IGDD is to use imaging to maximize effective therapy in diseased tissues and to minimize systemic drug exposure in order to reduce toxicities. Over the last several years, innumerable reports and reviews covering the gamut of IGDD technologies have been published, but inadequate attention has been directed toward identifying and addressing the barriers limiting clinical translation. In this consensus opinion, the opportunities and challenges impacting the clinical realization of IGDD‐based personalized medicine were discussed as a panel and recommendations were proffered to accelerate the field forward. WIREs Nanomed Nanobiotechnol 2014, 6:1–14. doi: 10.1002/wnan.1247
This article is categorized under:
Therapeutic Approaches and Drug Discovery > Emerging Technologies
Diagnostic Tools > In Vivo Nanodiagnostics and Imaging
Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease</abstract><cop>Hoboken, USA</cop><pub>John Wiley & Sons, Inc</pub><pmid>24339356</pmid><doi>10.1002/wnan.1247</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1939-5116 |
| ispartof | Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology, 2014-01, Vol.6 (1), p.1-14 |
| issn | 1939-5116 1939-0041 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1635020507 |
| source | MEDLINE; Access via Wiley Online Library |
| subjects | Animals Biomarkers Diagnostic software Diagnostic systems Drug delivery Drug Delivery Systems Drug discovery Humans Imaging Medical equipment Medicine Mice Molecular Imaging Nanomedicine Nanoparticles Nanotechnology Pharmaceutical industry Precision Medicine Tissues Toxicity Tumors |
| title | Assessing the barriers to image-guided drug delivery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T22%3A24%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Assessing%20the%20barriers%20to%20image-guided%20drug%20delivery&rft.jtitle=Wiley%20interdisciplinary%20reviews.%20Nanomedicine%20and%20nanobiotechnology&rft.au=Lanza,%20Gregory%20M.&rft.date=2014-01&rft.volume=6&rft.issue=1&rft.spage=1&rft.epage=14&rft.pages=1-14&rft.issn=1939-5116&rft.eissn=1939-0041&rft_id=info:doi/10.1002/wnan.1247&rft_dat=%3Cproquest_cross%3E3788832731%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1707438453&rft_id=info:pmid/24339356&rfr_iscdi=true |